RP-182 alleviated obstruction-induced renal fibrosis by reprogramming CD206⁺ macrophages.

ABSTRACT:

Introduction

Obstructive nephropathy is a major cause of chronic kidney disease (CKD), characterized by progressive renal fibrosis with limited treatment options. CD206⁺ macrophages have emerged as key drivers of fibrogenesis, yet targeted strategies against this subset remain undeveloped.

Methods

Using human ureteropelvic junction obstruction (UPJO) tissues and a murine unilateral ureteral obstruction (UUO) model, we assessed the accumulation of CD206⁺ macrophages and the progression of fibrosis. The therapeutic peptide RP-182, which selectively targets CD206, was administered daily to UUO mice. Histological, molecular, and flow cytometric analyses were performed to evaluate renal injury, fibrosis, inflammation, and macrophage polarization. In vitro

SUBMITTER: Cao H 

PROVIDER: S-EPMC12900717 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature